CA-PSMF
Patient Safety Movement Foundation (PSMF) – a global non-profit dedicated to unifying those involved in the healthcare ecosystem, identifying challenges that are causing patient deaths, and creating actionable solutions to mitigate them – is pleased to announce the appointment of its new chairman of the board of directors – Michael A.E. Ramsay, MD, FRCA. It also reaffirms its commitment to patient health and safety with updates to its mission, vision and values; and reestablishes its goal of achieving ZERO preventable patient deaths by 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200310005733/en/
As one of PSMF’s longest-standing board members, serving since 2013, Dr. Ramsay has been an advocate for patient safety in the anesthesia world since the 1980’s and embodies the values and principles set forth by the foundation. He is a renowned medical professional and the current president of the Baylor Scott & White Research Institute, where he spearheads clinically relevant research efforts. Well-known for the development and implementation of the Ramsay Sedation Scale – a tool that has been adopted globally, designed for interpreting the depth of sedation for patients in the critical care unit; he also serves as chairman of the Department of Anesthesiology and Pain Management at Baylor University Medical Center in Dallas, Texas.
“The Patient Safety Movement has achieved tremendous momentum in the eight years since its inception,” said Joe Kiani, founder and prior chairman of the board of the Patient Safety Movement Foundation. “Kindling this important movement has been an enormous part of my life’s work, and I am thrilled to pass the torch to Dr. Ramsay to carry our shared vision forward into the future with passion and enthusiasm.”
To date, the foundation has accomplished:
- Saving 366,353 lives since 2013
- Securing 48 countries with committed hospitals
- Securing 54 countries with partner groups (i.e. hospitals, open data pledge, other partners)
- Securing 4,793 total committed hospitals
- Securing 92 total pledges
- Securing 94 total partners
- Saving a total of 93,276 lives in 2019 alone
While the foundation did not achieve its prior goal of hitting zero preventable patient deaths by 2020, it renews the pledge with a new target goal of 2030.
“It is a great honor to be appointed chairman of the board of directors of the Patient Safety Movement Foundation,” states Dr. Ramsay. “Lives are being saved and patient harm is being prevented. We share monumentally important goals and have taken great leaps forward thus far; and I truly look forward to building upon the successes to date to achieve ZERO preventable patient deaths by 2030.” Dr. Ramsay has written his first “Letter from the Chairman” which is published monthly on the PSMF’s website. To read his first letter, visit: https://patientsafetymovement.org/newsletters/march-2020-issue-ii/letter-from-the-chairman-march-2020 .
The Patient Safety Movement Foundation will continue to provide tools, resources and guidelines aimed at educating healthcare providers, industry professionals, patients and families, to achieve its vision of a future that diminishes and ultimately eliminates preventable patient deaths. It will do so by:
- Prioritizing safety with patients at the center.
- Promoting dignity, compassion and respect in healthcare.
- Aligning everyone who influences or is touched by healthcare.
- Promoting transparency.
- Realigning incentives to achieve safer care.
- Informing caregivers, patients and families about patient safety.
- Identifying the preventable causes of patient harm and death, and then create and freely share actionable solutions (Actionable Patient Safety Solutions) to mitigate them.
- Driving the implementation of Actionable Patient Safety Solutions (APSS).
-
Asking healthcare technology companies to share data to create a Patient Data Superhighway.
To learn more about Patient Safety Movement Foundation, visit https://patientsafetymovement.org/ .
ABOUT PATIENT SAFETY MOVEMENT FOUNDATION: More than 200,000 people die every year in U.S. hospitals and 4.8 million worldwide in ways that could have been prevented. The Patient Safety Movement Foundation (PSMF) is a global non-profit working toward a future that diminishes and ultimately eliminates preventable patient deaths by offering tools, resources and guidelines aimed at educating healthcare providers, industry professionals, patients and families. It was established through the support of the Masimo Foundation for Ethics, Innovation and Competition in Healthcare to achieve the goal of ZERO preventable patient deaths. Achieving this goal requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers and private payers. The Patient Safety Movement Foundation is dedicated to unifying those involved in the healthcare ecosystem, identifying challenges that are causing patient deaths, creating actionable solutions to mitigate them, and partnering with hospitals who are committed to implementing its specific, high-impact solutions to meet patient safety challenges called Actionable Patient Safety Solutions (APSS) . The organization also encourages medical technology companies to share the data their products are purchased for, and asks hospitals to make commitments to implement Actionable Patient Safety Solutions. To learn more, visit patientsafetymovement.org.
Editor’s Note: To schedule interviews with the experts from Patient Safety Movement Foundation, please email jennifer@beyondfifteen.com or call 949.733.8679.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200310005733/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
